Mushrooms are a possible rich source of biologically active compounds with potential for drug discovery. The aim of this work was to gain further insight into the citotoxicity mechanism of action of Clitocybe alexandri ethanolic extract against a lung cancer cell line (NCI-H460 cells). The effects on cell cycle profile and levels of apoptosis were evaluated by flow cytometry, and the effect on the expression levels of proteins related to cellular apoptosis was also investigated by Western blot. The extract was characterized regarding its phenolic composition by HPLC-DAD, and the identified compounds were studied regarding their growth inhibitory activity, by sulforhodamine B (SRB) assay. The effect of individual or combined compounds on viable cell number was also evaluated using the Trypan blue exclusion assay. It was observed that the Clitocybe alexandri extract induced an S-phase cell cycle arrest and increased the percentage of apoptotic cells. In addition, treatment with the GI 50 concentration (concentration that was able to cause 50% of cell growth inhibition; 24.8 µg/ml) for 48h caused an increase in the levels of wt p53, cleaved caspase-3 and cleaved poly (ADPribose) polymerase (PARP). The main components identified in this extract were protocatechuic, p-hydroxybenzoic and cinnamic acids. Cinnamic acid was found to be the most potent compound regarding cell growth inhibition. Nevertheless, it was verified that the concomitant use of the individual compounds provided the strongest decrease in viable cell number. Overall, we found evidence for alterations in cell cycle and apoptosis, involving p53 and caspase-3. Furthermore, our data suggests that the phenolic acids identified in the extract are at least partially responsible for the cytotoxicity induced by this mushroom extract.
Introduction
Cancer is a leading cause of death worldwide and accounted for 7.6 million deaths (around 13% of all deaths) in 2008. Cancer related deaths are projected to increase to over 11 million in 2030 (World Health Organization, 2010) . Lung cancer is the major cancer killer (being responsible for an estimated 1.4 million deaths in 2008) and a health care problem worldwide with an overall 5-year survival rate of less than 15% (Brescia, 2001; Poleri et al., 2003) .
Empirical approaches to discover anticancer drugs and cancer treatments have made limited progress in the past several decades in finding a cure for cancer. The vast structural diversity of natural compounds found in mushrooms (macrofungi) provided unique opportunities for discovering new drugs (Zaidman, Yassin, Mahajana, & Wasser, 2005) . Mushrooms have been valued as edible and medicinal resources, and antitumor substances have been identified in many mushrooms species (Zhang, Cui, Cheung, & Wang, 2007) . There is a significant interest in the use of mushrooms and/or mushroom extracts as dietary supplements based on the theory that they enhance immune function and promote health (Borchers, Keen, & Gershwin, 2004) . Particularly, they can be added to the diet and used orally and they are considered as a safe and useful approach for disease treatment.
Different molecules found in fruiting bodies, mycelia and spores of macrofungi revealed antitumor potential (Moradali, Mostafavi, Ghods, & Hedjaroude, 2007) , such as highmolecular-weight compounds (e.g. polysaccharides, glycoproteins, proteoglycans and proteins) and low-molecular-weight compounds (e.g. quinones, cerebrosides, isoflavones, catechols, amines, triacylglycerols, sesquiterpenes and steroids) . Among the mentioned compounds, polysaccharides (primary metabolites) are the best studied mushroom-derived 4 substances with antitumor properties (Wasser, 2002; Zhang, Cui, Cheung, & Wang 2007) , while the study of mushrooms secondary metabolites such as phenolic compounds have been overlooked.
Phenolic compounds are aromatic hydroxylated compounds, are commonly found in many food sources and some of them are among the most potent and therapeutically useful bioactive substances. Natural phenolic compounds accumulate as end-products from the shikimate and acetate pathways and can range from relatively simple molecules (phenolic acids, phenylpropanoids, flavonoids) to highly polymerised compounds (lignins, melanins, tannins) (Bravo, 1998) . The main phenolic compounds found in mushrooms are phenolic acids: hydroxybenzoic and hydroxycinnamic acids, which are derived from the non-phenolic molecules benzoic and cinnamic acid, respectively (Ferreira, Barros, & Abreu, 2009 ).
Clitocybe alexandri is an edible saprophytic Basidiomycotina mushroom belonging to the family of Tricholomataceae that can be found wildly in Northeast Portugal. We have recently reported the growth inhibitory activity of methanolic, ethanolic and boiling water extracts from Clitocybe alexandri, in human tumour cell lines (NCI-H460, MCF-7, HCT-15 and AGS) . The ethanolic extract was the most potent one, particularly in NCI-H460 cells (GI 50 24.8 ± 2.3 µg/ml) . Herein, we intend to further evaluate the potential of this extract as a possible source of cytotoxic compounds.
Materials and methods

Standards and reagents
Ethanol was of analytical grade purity and supplied by Pronalab (Lisbon, Portugal). 
Samples and sample preparation
Samples of Clitocybe alexandri (Gillet) Gillet (edible mushroom) were collected under Quercus pyrenaica Willd, in Bragança (Northeast Portugal), in autumn 2008.
Taxonomic identification of sporocarps was made according to Moreno (2005) and online keys (http://www.mycokey.com/), and representative voucher specimens were deposited at the herbarium of Escola Superior Agrária of Instituto Politécnico de Bragança. The samples were lyophilised (Ly-8-FM-ULE, Snijders, Holland) and reduced to a fine powder (20 mesh).
The ethanolic extract was prepared from the lyophilised powder (extraction yield 3.5 ± 0.2%) following the procedure previously described by us . For the assays, the extract was re-dissolved in DMSO and diluted in media to the final concentrations used: GI 50 (24.8 µg/ml) or 2 × GI 50 (49.6 µg/ml). The GI 50 was previously obtained from the growth inhibitory activity of C. alexandri ethanolic extract in NCI-H460 cells .
Cell line
6 NCI-H460 (non-small cell lung cancer) were routinely maintained as adherent cell cultures in RPMI-1640 medium with 5% heat-inactivated FBS, in a humidified incubator at 37 ºC with 5% CO 2 . All assays were performed with cells in exponential growth, with viabilities over 90% and repeated at least in three independent experiments.
Cell cycle distribution analysis and apoptosis detection
For the analysis of cell cycle phase distribution, NCI-H460 cells were plated at 1.5 ×
10
5 cells/ml in 6-well plates and left incubating for 24 hours. Cells were then incubated with complete medium only (blank), medium with the solvent DMSO or with C.
alexandri ethanolic extract at GI 50 (24.8 µg/ml) and 2 × GI 50 (49.6 µg/ml)
concentrations. The GI 50 concentration had been previously determined by the SRB assay . Cells were harvested following a 48 h incubation with the extract and further processed for either cell cycle analysis or apoptosis detection. For cell cycle analysis, cells were fixed in 70% ethanol for 10 min at room temperature.
After centrifugation cells were incubated with PI (5 µg/ml) and RNase A in PBS (100 µg/ml) for 30 min on ice (Vasconcelos et al., 2000; Palmeira et al., 2010) . Induced apoptosis was assayed by the Human Annexin V-FITC/PI apoptosis Kit (Bender MedSystems, Vienna, Austria) according to the manufacturer's instructions (Queiroz et al., 2011) .
Cellular DNA content (for cell cycle distribution analysis and presence of sub-G1 peak, suggestive of apoptosis induction) and measurement of phosphatidylserine externalization were analyzed using an Epics XL-MCL Coulter flow cytometer plotting at least 20,000 events per sample. Cell cycle distribution and apoptosis data analysis were subsequently performed using the FlowJo 7.2 software (Tree Star, Ashland, USA).
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Three to six independent experiments were performed in duplicate and the results were expressed as mean values ± standard deviation (SD). Statistical analysis was performed by the non-parametric Friedman's test followed by Dunn's Post-test using GraphPad
Prism 5 software. P values < 0.05 were considered as statistically significant.
Protein expression analysis
For analysis of protein expression, NCI-H460 cells were treated with complete medium (blank), medium with the solvent (DMSO) or with C. alexandri ethanolic extract at 24.8 µg/ml, the GI 50 concentration previously determined by the SRB assay , and processed 48 h after incubation. The mobile phase and the gradient employed were described previously (Vaz et al., 2011) . Injection volume was 20 µl.
Detection was carried out in a diode DAD, using 280 nm as the preferred wavelength.
The effects of the identified compounds (protochatequic, p-hydroxibenzoic and cinnamic acids) on the growth of NCI-H460 were evaluated according to the procedure adopted in the NCI's in vitro anticancer drug screening, which uses SRB assay to assess cell growth inhibition (Skehan et al., 1990) . This colorimetric assay estimates cell number indirectly, by staining cellular protein with the protein-binding dye SRB. For such, the cell line was plated at an appropriate density (5.0 × 10 3 cells/well) in 96-well plates and allowed to attach for 24 h. Cells were then treated for 48 h with various concentrations of the compounds. Following this incubation period, the adherent cells were fixed with 10% trichloroacetic acid, washed with 1% acetic acid and stained with SRB. The bound stain was solubilised with 10 mM Tris and the absorbance was measured at 490 nm in a microplate reader (BIORAD 680 model). The concentration that inhibited growth in 50% (GI 50 ) was calculated as described by Monks et al. (1991) .
The growth inhibitory activity of the compounds was inferred from the SRB assay by comparing the absorbance of the wells containing extract-treated cells with the absorbance of the wells containing untreated cells, 48 h following treatment with the compounds, and subsequently comparing these results with the ones obtained for cells 9 that had been fixed at time zero (time at which the extracts were added) . Doxorubicin was tested in the same manner to be used as a positive control.
Three to six independent experiments were performed in duplicate and the results were expressed as mean values ± standard deviation (SD).
Viable cell number
Viabel cell number was determined with the trypan blue dye exclusion test (Renzi, Valtolina, & Foster, 1993) by the non-parametric Friedman's test followed by Dunn's Post-test using GraphPad Prism 5 software. P values < 0.05 were considered as statistically significant.
Results and discussion
Effect of Clitocybe alexandri estract on cell cycle profile and levels of apoptosis
The most active Clitocybe alexandri extract-the ethanolic extract-reported in our previous study concentration (24.8 µg/ml) of the extract for 48 h had 7.3% ± 2.1% of apoptotic cells, similarly to the blank.
Furthermore, the effect of the mushroom extract on the expression of some proteins involved in the apoptotic process was determined by Western blot. Results show that treatment of NCI-H460 cells with the GI 50 concentration (24.8 µg/ml) of the extract for 48 h caused an increase in the levels of wt p53, cleaved caspase-3 and cleaved PARP (Figure 2) .
Chemical characterization of the extract and further evaluation of the effect of the identified compounds on cell growth and viable cell number
The ethanolic extract was analysed by HPLC-DAD, and two phenolic acids and a related compound were identified (Figure 3) and quantified: protocatechuic acid (16.4 ± 11 2.2 mg/kg of dry weight), p-hydroxybenzoic acid (8.3 ± 0.4 mg/kg of dry weight) and cinnamic acid (6.4 ± 0.3 mg/kg of dry weight).
The in vitro NCI-H460 growth inhibitory activity of the identified compounds was evaluated by SRB assay, after a continuous treatment during 48 h. Cinnamic acid was found to be the most potent compound regarding cell growth inhibition (GI 50 value 845.9 ± 97.5 µM) (Figure 4) . Protocatechuic acid revealed a GI 50 value of 1616.9 ± 75.3 µM, while p-hydroxybenzoic acid did not show any activity at the highest tested concentration tested (3000 µM) (Figure 4) . Despite the much lower GI 50 value obtained for the positive control Doxorubicin (0.07 ± 0.02 µM), it should be highlighted that phenolic acids are natural compounds and can act synergistically with other compounds present in the mushroom extract. Therefore, the comparisons between the positive control (highly toxic synthetic compound) and the individual compounds found in the extract, and mostly with the whole extract, should be made carefully. Overall, the results reported here are related to the cytotoxicity of Clitocybe alexandri in a non-small lung cancer cell line. We found evidence for alterations in cell cycle and apoptosis, involving p53 and caspase-3. Other studies using extracts of plants like
Euchresta formosana and Angelica sinensis (Cheng, et al., 2011; Hsu, et al., 2007 ) also reported similar effects to the ones observed for Clitocybe alexandri extract.
Finally, our data suggests that the phenolic acids identified in the ethanolic extract are at least partially responsible for the cytotoxicity induced by this mushroom extract and that they exert a concomitant effect. Further studies will include analysis of effect in nontumour cells and the identification of other compounds in the extract. Only peaks corresponding to phenolic compounds or related compounds are indicated:
(1) protocatechuic acid, (2) p-hydroxybenzoic acid and (3) cinnamic acid. 
